Donald Junge, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1316 S Main St, Clarion, IA 50525 Phone: 515-532-2811 Fax: 515-532-9336 |
News Archive
Trius Therapeutics, Inc. announced that the first patient has been dosed in its Phase 3 clinical study of the oral dosage form of torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The double-blind, active control, pivotal study is designed to compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate for six days of treatment with the efficacy and safety of twice-daily oral administration of 600 milligrams of linezolid (Zyvox®) for 10 days of treatment.
A new, highly sensitive method to detect genetic variations that initiate colon cancer could be readily used for noninvasive colon cancer screening, according to a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
Oxford Gene Technology, The Molecular Genetics Company, has expanded its SureSeq myPanel™ NGS Custom Cancer Panel content - now covering 120 fully optimized cancer related genes.
Researchers from the National Institute of Standards and Technology (NIST) and the German national metrology institute have used NIST's miniature atom-based magnetic sensor to successfully track a human heartbeat, confirming the device's potential for biomedical applications.
New Mayo Clinic research studied the association between prostate-specific antigen (PSA) levels and prostate size and found that routine annual evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer.
› Verified 6 days ago